Evaluate Antimicrobial Agents to Treatment of Urine Tract Infection Caused by E. coli and ESBL-Producing E. coli.

Jamal S. Haider; Mustafa E.  Elsharief

doi:10.59743/jmset.v1i1.140

Authors

Jamal S. Haider Faculty of Dental Surgery Alasmarya Islamic University, Libya.
Mustafa E. Elsharief Faculty of Marine Resources, Alasmarya Islamic University, Libya.

DOI:

https://doi.org/10.59743/jmset.v1i1.140

Keywords:

UTI, ESBL-producing, E. coli

Abstract

Escherichia coli is the most common pathogen of bacterial infections worldwide. As many as 80% of urinary tract infections are caused by E. coli. Infections caused by extended-spectrum β-lactamase (ESBL)–producing gram-negative bacteria are occurring more frequently in hospitalized patients. These organisms can cause a variety of infections including, but not limited to, pneumonia, urinary tract infections, and bacteremia. Carbapenems are considered the drugs of choice for ESBL-producing bacteria.

Retrospective study of patients with ESBL-producing E. coli. were taken retrospectively from Phoenix 100. The result shows that the percentage of ESBL-produced E. coli was 27.5% from total E. coli isolation. None of the 59 isolates (E. coli with no resistant marker and ESBL-producing E. coli) show resistance to ertapenem, meropenem, or promising made them promising as a therapy for ESBL-producing E. coli. The result shows also a high rate of resistance to quinolons (Ciprofloxacine, Cephalothin, Cefrazidime, Levofoxacin) in ESBL-producing E. coli with a resistance rate of >60% (Table1), must be ruled out as a therapy option for the treatment of UTIs caused by ESBL- producing organisms.

References

Alhambra A., Cuadros J.A., Cacho J., Gomez-Garces J.L., and Alos J.I. (2004). In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J. Antimicrob. Chemother, 53: 1090-1094.

Bradford P.A. (2001). Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. Clinical Microbiology Reviews, 14: 933-951.

Chaudhary U., and Aggarwal R. (2004). Extended spectrum -lactamases (ESBL) - An emerging threat to clinical therapeutics. Indian J. Med. Microbiol., 22:75-80

FDA (2015). Available online: [http://www.drugs.com/pro/nitrofurantoin-capsules.html].

Livermore D.M., Canton R., Gniadkowski M., Nordmann P., Rossolini G.M., Arlet G., Ayala J., Coque T. M., Kern-Zdanowicz I., Luzzaro F., Poirel L., and Woodford N. (2007). CTX-M: changing the face of ESBLs in Europe. Journal of Antimicrobial Chemotherapy, 59: 165–174

Machado E., Coque T.M., Canton R., Baquero F., Sousa J.C., and Peixe L. (2006). Dissemination in Portugal of CTX-M-15-, OXA-1-, and TEM-1-Producing Enterobacteriaceae Strains Containing the aac(6′)-Ib-cr Gene, Which Encodes an Aminoglycoside- and Fluoroquinolone- Modifying Enzyme. Antimicrobial Agents and Chemotherapy, 50: 3220-3221

Mody R.M., Erwin D.P., Summers A.M., Carrero H.A., Selby E.B., Ewell A.J., and Moran K.A. (2007). Ertapenem susceptibility of extended spectrum beta-lactamase- producing organisms. Annals of Clinical Microbiology and Antimicrobials, 6(1): 6.

Morosini M.I., Garcia-Castillo M., Coque T.M., Valverde A., Novais A., Loza E., Baquero F., and Canton R. (2006). Antibiotic coresistance in extended-spectrum-beta- lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrobial Agents and Chemotherapy, 50: 2695-2699.

Paterson D.L. (2006). Resistance in gram-negative bacteria: Enterobacteriaceae. American Journal of Medicine, 119: S20-S28.

Paterson D.L., and Bonomo R.A. (2005). Extended-spectrum beta-lactamases: a clinical update. Clinical Microbiology Reviews, 18(4): 657–686

Perez F., Endimiani A., Hujer K.M., and Bonomo R.A. (2007). The continuing challenge of ESBLs. Current Opinion in Pharmacology, 7: 459-469.

Schito G.C., Naber K.G., Botto H., Palou J., Mazzei T., Gualco L., and Marchese A. (2009). The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int. J. Antimicrob Agents, 34: 407-413.

Schwaber M.J., Navon-Venezia S., Schwartz D., and Carmeli Y. (2005). High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 49: 2137-2139.

Shah P.M. (2008). Parenteral carbapenems. Clin. Microbiol. Infect., 14 (1):175– 180.

Tamayo J., Orden B., Cacho J., Cuadros J., Gomez-Garces J.L., and Alos J.I. (2007). Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid, Rev. Esp. Quimioter., 20: 334-338.

Turner P.J. (2005). Extended-spectrum beta-lactamases. Clinical Infectious Diseases, 41: S273-S275.